
## **Claudia Kedor**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2089388/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). Journal of Translational Medicine, 2022, 20, 138.	1.8	116
2	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the Rheumatic Diseases, 2020, 79, 1090-1097.	0.5	56
3	Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Clinical Medicine, 2021, 10, 3675.	1.0	38
4	Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS. Journal of Translational Medicine, 2021, 19, 159.	1.8	31
5	SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Frontiers in Immunology, 2022, 13, 840126.	2.2	20
6	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD Open, 2021, 7, e001660.	1.8	19
7	A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome. Clinical Rheumatology, 2016, 35, 2203-2210.	1.0	15
8	Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology, 2021, 12, 644548.	2.2	14
9	Indate on the therapy of adult-onset Still's disease with a focus on II -1-inhibition; a systematic review	1.2	10
10	Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab. Journal of Clinical Medicine, 2021, 10, 4400.	1.0	6
11	Response to: â€~Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease' by Ruscitti <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e104-e104.	0.5	4
12	Response to abatacept is associated with the inhibition of proteasome $\hat{I}^2 Ii$ expression in T cells of patients with rheumatoid arthritis. RMD Open, 2020, 6, e001248.	1.8	3
13	Response to: â€~Correspondence on â€~Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova. Annals of the Rheumatic Diseases, 2022, 81, e234-e234.	0.5	3
14	Diagnostic accuracy of dual-energy computed tomography and joint aspiration: a prospective study in patients with suspected gouty arthritis. Clinical and Experimental Rheumatology, 2018, 36, 1061-1067.	0.4	3
15	THU0561â€CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILLâ€ <sup>-</sup> S DISEASE TO ACHIEVE REDUCTION ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER). , 2019, , .	N OF	1
16	Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study. SSRN Electronic Journal, 0, , .	0.4	1